TriNetX Speeds Drug Trials With Databricks

TriNetX, a major player in real-world health data, is accelerating drug development timelines by integrating Databricks' unified analytics platform. This move aims to tackle the significant costs and delays inherent in bringing new therapies to market.

Clinical trials are notoriously slow and expensive, with average costs soaring to $708 million per therapy and protocol amendments alone causing delays of around 260 days. TriNetX operates the world's largest federated real-world health data network, connecting researchers to insights from nearly 300 million patients across over 230 healthcare organizations. The company's mission is to make complex health data accessible and actionable for researchers, a goal that was strained by traditional data infrastructure as its network expanded.

The Challenge of Data Complexity

TriNetX faced the challenge of making vast, complex real-world health data (RWD) truly easy to use. High-quality, compliant, and immediately actionable data is crucial for its clients. This requires flexibility in data source selection, access methods, and the application of human or AI-driven intelligence.

The demand for advanced analytics, machine learning (ML), and intuitive AI experiences outpaced TriNetX's existing infrastructure. Pharmaceutical companies require tailored analytics and collaborative, compliant environments for their data science teams. TriNetX also sought to prepare its ecosystem for next-generation AI applications to democratize RWD insights and lower technical barriers for researchers.

Databricks Powers Innovation

To meet these demands, TriNetX adopted Databricks, establishing it as the centralized Lakehouse architecture for its consolidated RWD from electronic health records. This foundation supports TriNetX's vision for AI-powered data and analytics, allowing customers to work with RWD via self-service interfaces, custom APIs, or conversational AI.

The Databricks platform now hosts all custom datasets and pan-therapeutic data products. It also underpins TriNetX's consulting services, where data scientists develop sophisticated ML models and proprietary algorithms that operate across the entire network. TriNetX is further enhancing data accessibility with its beta Query Assistant, a conversational interface that allows researchers to ask complex questions in natural language, eliminating the need for programming expertise.

TriNetX is also prototyping a Support Assistant using Databricks' Agent Bricks, intended to evolve into a comprehensive feasibility assistant. This represents a significant shift in how customers access intelligence embedded within TriNetX's RWD.

Measurable Impact on Drug Development

The collaboration has yielded significant results. In 2025, TriNetX helped pharmaceutical clients reduce protocol amendments by up to 50%, keeping studies on track. Its AI-enhanced site identification achieved a 63% site acceptance rate with an average nine-day response time, vastly outperforming traditional feasibility workflows.

ML models developed on Databricks are demonstrating substantial predictive improvements. For inflammatory bowel disease studies, model outputs suggest enrollment conversion rates could jump from 33% to 85%. A pancreatic cancer risk prediction model, developed with leading institutions, identifies 87 features capable of forecasting disease development within 18 months. This model is currently undergoing validation on a prospective cohort of six million patients.

Looking ahead, TriNetX plans to deploy enhanced API capabilities in 2026, enabling pharmaceutical partners to submit study queries directly from their existing systems. These queries will return real-time patient counts and feasibility indicators, further accelerating study planning and paving the way for deeper agentic AI integration. TriNetX is exploring additional Databricks products like Genie to unlock new RWD use cases beyond feasibility and protocol design.